Free Trial

Design Therapeutics (DSGN) Competitors

Design Therapeutics logo
$4.04 -0.13 (-3.12%)
Closing price 04:00 PM Eastern
Extended Trading
$4.06 +0.01 (+0.37%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DSGN vs. OCS, CMRX, CDMO, QURE, CRMD, CRON, GHRS, SNDX, IMNM, and GYRE

Should you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Oculis (OCS), Chimerix (CMRX), Avid Bioservices (CDMO), uniQure (QURE), CorMedix (CRMD), Cronos Group (CRON), GH Research (GHRS), Syndax Pharmaceuticals (SNDX), Immunome (IMNM), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry.

Design Therapeutics vs. Its Competitors

Oculis (NASDAQ:OCS) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Design Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -13,788.70%. Design Therapeutics' return on equity of -22.85% beat Oculis' return on equity.

Company Net Margins Return on Equity Return on Assets
Oculis-13,788.70% -92.95% -70.03%
Design Therapeutics N/A -22.85%-22.02%

In the previous week, Oculis had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 3 mentions for Oculis and 0 mentions for Design Therapeutics. Oculis' average media sentiment score of 0.00 equaled Design Therapeutics'average media sentiment score.

Company Overall Sentiment
Oculis Neutral
Design Therapeutics Neutral

22.3% of Oculis shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 31.2% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Design Therapeutics has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oculis$780K1,029.93-$97.43M-$2.64-6.97
Design TherapeuticsN/AN/A-$49.59M-$0.99-4.08

Oculis presently has a consensus target price of $35.33, suggesting a potential upside of 92.03%. Design Therapeutics has a consensus target price of $4.00, suggesting a potential downside of 0.99%. Given Oculis' stronger consensus rating and higher possible upside, equities analysts clearly believe Oculis is more favorable than Design Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oculis
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Design Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Oculis has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500.

Summary

Design Therapeutics beats Oculis on 9 of the 14 factors compared between the two stocks.

Get Design Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DSGN vs. The Competition

MetricDesign TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$229.35M$2.96B$5.57B$9.02B
Dividend YieldN/A2.44%5.25%4.03%
P/E Ratio-4.0821.1127.2020.15
Price / SalesN/A260.29419.15184.83
Price / CashN/A41.8337.0657.97
Price / Book0.947.748.085.60
Net Income-$49.59M-$54.96M$3.16B$248.50M
7 Day Performance7.16%6.04%3.77%5.15%
1 Month Performance0.75%4.47%3.91%7.62%
1 Year Performance11.60%6.12%34.22%21.56%

Design Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DSGN
Design Therapeutics
0.3962 of 5 stars
$4.04
-3.1%
$4.00
-1.0%
+19.1%$229.35MN/A-4.0840
OCS
Oculis
1.7453 of 5 stars
$18.74
-1.4%
$35.33
+88.5%
+67.4%$829.58MN/A-7.102News Coverage
CMRX
Chimerix
0.6386 of 5 stars
$8.54
flat
$8.53
-0.1%
N/A$801.09M$212K-9.0990
CDMO
Avid Bioservices
0.8989 of 5 stars
$12.50
+0.1%
$12.25
-2.0%
+64.8%$799.18M$139.91M-5.23320High Trading Volume
QURE
uniQure
1.8544 of 5 stars
$14.31
-0.8%
$37.82
+164.3%
+122.9%$789.86M$27.12M-3.26500
CRMD
CorMedix
2.8188 of 5 stars
$11.42
-1.7%
$17.14
+50.1%
+164.0%$788.13M$82.55M51.9130
CRON
Cronos Group
2.2838 of 5 stars
$2.04
flat
N/A-7.1%$786.79M$117.61M15.69450News Coverage
GHRS
GH Research
2.0525 of 5 stars
$15.01
+0.7%
$32.00
+113.2%
+37.0%$776MN/A-19.0010News Coverage
SNDX
Syndax Pharmaceuticals
3.3168 of 5 stars
$8.73
-3.0%
$35.80
+310.1%
-59.1%$774.43M$23.68M-2.26110News Coverage
Analyst Forecast
Gap Up
IMNM
Immunome
1.9895 of 5 stars
$8.69
-1.7%
$23.33
+168.5%
-28.9%$769.19M$9.04M-2.7340
GYRE
Gyre Therapeutics
0.0872 of 5 stars
$7.62
-6.3%
N/A-36.1%$762.25M$105.76M381.1940

Related Companies and Tools


This page (NASDAQ:DSGN) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners